MEN2501
Insilico Medicine (licensed to Menarini; trial sponsor Stemline Therapeutics): company profile
Phase 1 registry
Since , the date of the source that reports this phase.
Summary
MEN2501 is a program from Insilico Medicine (licensed to Menarini; trial sponsor Stemline Therapeutics). The source describes it as small molecule. It is being developed for platinum-resistant ovarian cancer. ClinicalTrials.gov lists it at Phase 1 (recruiting) under NCT07226427. The AI role named in the source is molecule design. Registry records: NCT07226427, Phase 1, recruiting, updated Jul 6, 2026. About the company: Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation. First-in-human achieved; $5M milestone. The latest dated source is from Feb 11, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Insilico Medicine (licensed to Menarini; trial sponsor Stemline Therapeutics)
- Indication
- Platinum-resistant ovarian cancer
- Therapeutic area
- Oncology
- Modality
- Small molecule
- AI role
- Molecule design
- Phase in the source
- Phase 1, as of Feb 11, 2026
- Phase source
- Registry
- Board column
- Phase 1
Key readouts in the source
First-in-human achieved; $5M milestone
AI evidence
AI source: Company
“small molecule KIF18A inhibitor in development for chromosomally unstable solid tumors designed using Insilico’s generative AI engine.”
Trial records
- NCT07226427 on ClinicalTrials.gov (opens in new tab) Phase 1 Recruiting Updated
Milestone timeline
-
Official X post: Phase 1
First-in-human achieved; $5M milestone
-
NCT07226427 record updated
Phase 1, Recruiting
-
Registry check
Registry sponsor Stemline (Menarini group).
About Insilico Medicine
Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation.
Spot an error? Tell me and I'll fix it.